Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Apr;30(2):214-8.
doi: 10.4103/0970-1591.126909.

BPH and prostate cancer risk

Saiful Miah  1 , James Catto  1
Affiliations

BPH and prostate cancer risk

Saiful Miah et al. Indian J Urol. 2014 Apr.

Abstract

Introduction: With the exclusion of non-melanomatous skin malignancy, prostate cancer (PCa) is the second most prevalent cancer in men globally. It has been reported that the majority of men will develop benign prostatic hyperplasia (BPH) by the time they reach their 60s. Together, these prostatic diseases have a significant morbidity and mortality affecting over a billion men throughout the world. The risk of developing prostate cancer of men suffering BPH is one that has resulted in a healthy debate amongst the urological community. Here, we try to address this conundrum with clinical and basic science evidence.

Materials and methods: Data from an online search and contemporary data presented at international urological congresses was reviewed.

Results: BPH and PCa can be linked together at a molecular and cellular level on genetic, hormonal, and inflammatory platforms suggesting that these prostatic diseases have common pathophysiological driving factors. Epidemiological studies are weighted towards the presence of BPH having a greater risk for a man to develop PCa in his lifetime; however, a conclusion of causality cannot be confidently stated.

Conclusion: The future workload healthcare practitioners will face regarding BPH, and PCa will substantially increase. Further basic science and large epidemiological studies using a global cohort of men are required prior to the urological community confidently counseling their patients with BPH with regards to their PCa risk.

Keywords: Benign prostatic hyperplasia; epidemiology; epigenetics; genetics; inflammation; prostate cancer.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

References

    1. McVary KT. BPH: Epidemiology and comorbidities. Am J Manag Care. 2006;12(5 Suppl):S122–8. - PubMed
    1. McNeal JE. Normal histology of the prostate. Am J SurgPathol. 1988;12:619–33. - PubMed
    1. Bostwick DG, Cooner WH, Denis L, Jones GW, Scardino PT, Murphy GP. The association of benign prostatic hyperplasia and cancer of the prostate. Cancer. 1992;70(1 Suppl):291–301. - PubMed
    1. Chokkalingam AP, Nyren O, Johansson JE, Gridley G, McLaughlin JK, Adami HO, et al. Prostate carcinoma risk subsequent to diagnosis of benign prostatic hyperplasia: A population-based cohort study in Sweden. Cancer. 2003;98:1727–34. - PubMed
    1. Alcaraz A, Hammerer P, Tubaro A, Schroder FH, Castro R. Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review. EurUrol. 2009;55:864–73. - PubMed